Buehler?
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 2107
- Joined: Fri Jul 20, 2018 5:13 pm
Buehler?
Buhler? Buehler? Buehler? Buehler? How many times did questions need to be repeated? Why because management people were not paying attention. Pay attention! Obviously the call was staffed by remote attendees, with a substandard quality of technical sound. Maybe try coming into the office? Faye, a ligit question regarding the slow enrollments was asked. It was worthy of a much more detailed answer (kudos to the analyst who had the presence of mind to ask). After all we have watched the timeline extended and extended. Naturally some of that might be that patients are indeed living longer (great!), but some is related to glacial enrollments. There are 217 participating centers. Approx 256 patients enrolled to date. If each study center just enrolled one patient each in the next month the study would be over subscribed by about 150. The question was worthy of a more substantial answer. In the mean time the unfortunate truth is that we have to wait for patients to die. It is good for data collection the longer the study goes on but it is bad for patients waiting to get this drug for treatment. It takes me back to Fishermangents who asked me almost a decade ago to assume moderation of this board. This study can be stopped early for futility (that hasn’t happened) or obvious efficacy (well that hasn’t happened either). The DMSB needs to grow a pair and stop the study if the data is there (yes the data is blinded to them but they know what they are seeing and would know something about who is on drug). Otherwise are we really looking at another 18 months???? If the drug weren’t working, 18 months would take us well past the median OS for all untreated R/R control patients. And that’s if the study (enrolled at the 80% level) were initiated today. The study of course started in 2022. In other words most of the entire control group would be gone. There is no way this study can be allowed to go until the second half of 2026 for top line. That is unless the goal posts are moved again. Q 1 2027 anyone? Sorry Fish, I had no idea what I signed on for. Only hope I can keep my promise to you. (I am honor bound to.) bp